USA: Researchers have found in a new study that patients with idiopathic intracranial hypertension (IIH) treated with ...

DelveInsight's“ Obesity Pipeline Insigh t 2025 ” report provides comprehensive insights about 80+ companies and 100+ pipeline ...

According to a new report from Big Chalk Analytics, GLP-1 users have cut $6.5 billion from U.S. grocery spend.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best oversold NASDAQ stocks to buy now. On June 30, H.C. Wainwright ...

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

ERA Congress 2025 marked a pivotal moment in nephrology this year, bringing together over 9,000 global experts to explore ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

A recent Mercer survey reveals that over half of large employers plan to shift more health care costs to employees amid rising expenses expected in 2026.

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

S. Daniel Abraham, a onetime traveling salesman who started a line of weight-loss products led by the popular Slim-Fast diet drinks and who later used his fortune as a major Democratic political donor ...